Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee College of Veterinary Medicine to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium for Canine Soft Tissue Sarcomas
June 28, 2023 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 28, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with the University of Tennessee College of...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces U.S. Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma), and Metastatic Melanoma.
June 26, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in multiple...
Provectus Biopharmaceuticals Announces Stockholder Approval to Undertake Reverse Split of Outstanding Equities and Reduce Number of Authorized Equities by Same Ratio
June 26, 2023 07:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 26, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company’s shareholders have approved the proposals of Provectus’s Board of Directors (Board) to seek...
Global Breast Cancer Immunotherapy Market Size & Trends
June 20, 2023 10:08 ET
|
Global Market Estimates
Brooklyn, New York, June 20, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Breast Cancer Immunotherapy Market is projected to...
Global Immuno-Oncology Thematic Intelligence Report 2023: Focus on Trends in Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Checkpoint Modulators, Cytokines, & Oncolytic Viruses
June 13, 2023 04:48 ET
|
Research and Markets
Dublin, June 13, 2023 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Thematic Intelligence" report has been added to ResearchAndMarkets.com's offering.This report includes coverage of immuno-oncology...
Global STAT3 Inhibitors Market & Clinical Trials Outlook Report 2023-2028: Insights by Country, Indication, Organization & Phase
June 02, 2023 05:03 ET
|
Research and Markets
Dublin, June 02, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
May 30, 2023 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
Results Add to Growing Body of Evidence that Inhibiting PP2A with LB-100 May Be a General Method for Enhancing the Effectiveness of Immunotherapy in Refractory Cancers PASADENA, CA, May 30, 2023 ...
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
May 25, 2023 17:00 ET
|
Evaxion Biotech
Evaxion developed a genetic adjuvant technology that boosts the immune responses of viral, bacterial and cancer vaccinesPreclinically validated for both DNA and mRNA vaccines, and ready for clinical...
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
May 25, 2023 17:00 ET
|
Evaxion Biotech
Positive clinical response as demonstrated in 8 out of 12 patients receiving EVX-01 in combination with a checkpoint inhibitor The study met primary endpoints for tolerability and safety COPENHAGEN,...
ImmunOs Therapeutics Announces Initiation of Dosing in Phase 1 Trial of Lead Compound IOS-1002
May 24, 2023 04:00 ET
|
AKAMPION
- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...